BPC September 10 update

Mersana MRSN +40% P1 interim data; Endo ENDP opioid settlement +33%

Price and Volume Movers

Mersana Therapeutics (NASDAQ: MRSN) announced interim data from its Phase 1 trial of Upifitamab Rilsodotin (UpRi/ XMT-1536) in patients with ovarian cancer. Only 2 complete responses out of the 75 patients (2.6%) were noted, while the overall response rate came in at 23% among all patients (17/75). 22 patients were not evaluable, predominantly due to deaths (10) and withdrawals (5). Of the 97 patients, 43 (44%) had dose delay, reduction, and/or discontinuation due to Treatment-Related Adverse Events (TRAEs). Shares declined 40% at $8.55.

Endo International plc (NASDAQ: ENDP) announced that it settled three New York State opioid cases. The settlement noted no admission of wrongdoing, fault, or liability and includes a total payment of $50 million. Shares closed up 33% at $2.78.

Impel NeuroPharma, Inc. (NASDAQ: IMPL) announced the pricing of its offering of 3 million shares at $15 per share for gross proceeds of $45 million. Shares closed down 24% at $16.17.

AzurRx BioPharma, Inc. (NASDAQ: AZRX) announced that it will effect a 1-for-10 reverse stock split. Shares will begin trading on a split-adjusted basis at the market open on September 13, 2021. closed down 15% at $0.55.

Advancers

CompanyPriceChange
CRVS
Corvus Pharmaceuticals Inc.
$5.32+3.06  +135.40%
IPHA
Innate Pharma S.A.
$8.10+2.35  +40.87%
CYDY
Cytodyn Inc
$2.01+0.37  +22.56%
SURF
Surface Oncology Inc.
$7.10+1.09  +18.14%
ATNM
Actinium Pharmaceuticals Inc. (Delaware)
$7.83+1.15  +17.22%
EVLO
Evelo Biosciences Inc.
$8.34+1.03  +14.09%
MGTA
Magenta Therapeutics Inc.
$7.79+0.92  +13.39%
CNTB
Connect Biopharma Holdings Limited
$23.06+2.51  +12.21%
TRVN
Trevena Inc.
$1.36+0.14  +11.48%
FULC
Fulcrum Therapeutics Inc.
$30.83+3.14  +11.34%

Decliners

CompanyPriceChange
PTGX
Protagonist Therapeutics Inc.
$17.53-28.6  -62.00%
TCRR
TCR2 Therapeutics Inc.
$9.99-5.73  -36.45%
ELYM
Eliem Therapeutics Inc
$18.77-5.27  -21.92%
JANX
Janux Therapeutics Inc.
$27.39-6.96  -20.26%
ICVX
Icosavax Inc.
$33.06-6.4  -16.22%
IPSC
Century Therapeutics Inc.
$24.76-4.49  -15.35%
GRTS
Gritstone bio Inc.
$11.50-2.04  -15.07%
VERV
Verve Therapeutics Inc.
$59.88-9.99  -14.30%
INAB
IN8bio Inc.
$7.00-1.09  -13.47%
TNYA
Tenaya Therapeutics Inc.
$20.85-3.2  -13.31%

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

ALRN – Aileron Therapeutics Inc.
ALRN-6924
Healthy volunteers

$1.17
+0.09  +8%
Phase 1 Phase 1 preliminary data showed a 0.3 mg/kg dose demonstrated favorable tolerability, with subjects experiencing only mild, transient adverse events, noted September 16, 2021
$105.9 million

AZRX – AzurRx BioPharma Inc.
Oral niclosamide (RESERVOIR)
COVID-19

$3.75
-0.09  -2%
Phase 2 Phase 2 top-line data due 1Q 2022.
$35 million

BYSI – BeyondSpring Inc.
Plinabulin (Trial 103) - DUBLIN-3
Non small cell lung cancer - refractory

$22.91
+0.40  +2%
Phase 3 Phase 3 top-line data met primary endpoint of overall survival (p = 0.03) - August 4, 2021. Late breaker at ESMO September 20, 2021. NDA Submission for plinabulin in NSCLC 1H 2022.
$698.6 million

BYSI – BeyondSpring Inc.
Plinabulin + OPDIVO (nivolumab) + YERVOY (ipilimumab)
Small-cell lung cancer (SCLC)

$22.91
+0.40  +2%
Phase 2 Phase 2 data due 2022.
$698.6 million

BYSI – BeyondSpring Inc.
Plinabulin + PD-1/PD-L1 inhibitor and radiotherapy
Solid Tumors

$22.91
+0.40  +2%
Phase 1/2 Phase 1b initiation of dosing announced June 4, 2021. Phase 1 data due 2022.
$698.6 million

HEPA – Hepion Pharmaceuticals Inc.
CRV431 (ASCEND-NASH)
Non-alcoholic steatohepatitis

$1.59
+0.01  +1%
Phase 2b Phase 2a data released July 13, 2021. Primary endpoints met. Further Phase 2a data presented on September 13, 2021. Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431, PK-PD models successfully predict early reductions in Pro-C3 and ALT. Phase 2b activities initiated September 13, 2021.
$121.2 million

INAB – IN8bio Inc.
INB-200
Glioblastoma

$7.00
-1.09  -13%
Phase 1 Phase 1 preliminary data presented at ASCO June 4, 2021. INB-200 was generally well tolerated with no observed infusion reactions. Additional Phase 1 data due end of 2021.
$131.3 million

INAB – IN8bio Inc.
INB-100
Allogeneic hematopoietic stem cell transplantation (HSCT)

$7.00
-1.09  -13%
Phase 1 Phase 1 initial data due in 2022, with top-line data due in 2023. Completion of dosing of first cohort announced August 11, 2021.
$131.3 million

MRSN – Mersana Therapeutics Inc.
Upifitamab Rilsodotin (XMT-1536) - UPLIFT
Ovarian Cancer, Non Small Cell Lung Cancer

$9.89
+0.18  +2%
Phase 1 Phase 1 initial data released September 10, 2021. Complete response rate 2.6% (2/75); overall response rate 23% (17/75) in all patients. 22 patients not evaluable.
$709.7 million

NYMX – Nymox Pharmaceutical Corporation
Fexapotide Triflutate (NX-1207)
BPH

$1.89
-0.20  -10%
NDA Filing NDA filing initially planned by September 15, 2021 has been delayed. Company expects filing soon and will update within 30 days - noted September 10, 2021.
$158.3 million

OMGA – Omega Therapeutics Inc.
OTX-2002
Hepatocellular Carcinoma

$21.96
-0.43  -2%
Phase 1 IND expected 1H 2022.
$1 billion